Here is the design of a clinical trial:

Official Title: Adjuvant Nab-paclitaxel Plus S-1 Versus Capecitabine Plus Oxaliplatin for Patients With Stage III Gastric Cancer After D2 Gastrectomy : a Randomised，Open-label, Phase III Study

Included conditions:
- Stomach Cancer

Study Armgroups:
- {'label': 'AS', 'type': 'EXPERIMENTAL', 'description': 'Arm A：nab paclitaxel （120mg/m2；iv；d1，8）+S-1 （\\<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）Q3W；up to eight cycles', 'interventionNames': ['Drug: nab paclitaxel', 'Drug: Tegafur']}
- {'label': 'XELOX', 'type': 'ACTIVE_COMPARATOR', 'description': 'Arm B：Capetabine（1000 mg/m2 po, d1-14 bid ）+ Oxaliplatin（130mg/m2 , iv, d1）Q3W；up to eight cycles', 'interventionNames': ['Drug: Oxaliplatin', 'Drug: Capecitabine']}

Interventions:
- {'type': 'DRUG', 'name': 'nab paclitaxel', 'description': 'nab paclitaxel （120mg/m2；iv；d1，8）', 'armGroupLabels': ['AS'], 'otherNames': ['albumin bound paclitaxel']}
- {'type': 'DRUG', 'name': 'Tegafur', 'description': 'S-1 （\\<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）', 'armGroupLabels': ['AS'], 'otherNames': ['S-1']}
- {'type': 'DRUG', 'name': 'Oxaliplatin', 'description': 'Oxaliplatin（130mg/m2 , iv, d1）', 'armGroupLabels': ['XELOX']}
- {'type': 'DRUG', 'name': 'Capecitabine', 'description': 'Capetabine（1000 mg/m2 po, d1-14 bid ）', 'armGroupLabels': ['XELOX']}

Primary Outcomes:
- {'measure': '3 years Diseases-free Survival rate(3 years-DFS)', 'description': 'DFS is defined as time from the date of inclusion up to the date of disease progression or death', 'timeFrame': 'up to 3 years'}

Please estimate the sample size based on the assumption: 
Type I error (bilateral) α=0.05, test efficacy β=0.8, hazard ratio (HR) of 0.66, and estimated drop-out rate of 10%.
Sample size
        In this trial, the patients will be hierarchically grouped by a network multicenter central stochastic system. The subjects will be randomized by the system after screening. This study uses DFS as the main evaluation index. According to the CLASSIC study, the 3-year DFS rates of patients with IIIA and IIIB gastric adenocarcinoma who received XELOX regimen are 66 and 61%, respectively [7]. According to the ACTS-GC trial, the 3-year recurrence-free survival (RFS) rate of patients with stage III gastric cancer who received S-1 adjuvant chemotherapy (sixth edition of International Union Against Cancer (UICC) TNM classification) is 69.1% in stage IIIA and 44.8% in stage IIIB [11]. The 3âyear-DFS rate of patients with stage III gastric adenocarcinoma who received nab-paclitaxel combined with S-1 treatment is estimated to be 71%. Considering type I error (bilateral) Î±=0.05 and the test efficacy Î²=0.8, hazard ratio (HR) of 0.66, and estimated drop-out rate of 10%, about 616 patients will be randomly enrolled in the clinical study, with a total study period of about 60âmonths.